Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | Shattock: Novel Antigens for Mucosal Protection |
| Strategy: | Protein & peptide vaccines |
| Study Type: | Pre-Clinical NHP |
| Species: | Cynomolgus macaque |
| Stage: | Assays Completed |
| Study Start Date: | 2009-06-10 |
| Study Made Public: | 2011-09-30 |
Title
Neutralization activity of sera collected from cynomolgus macaques immunized by the intravaginal and/or intramuscular routes with a recombinant clade C HIV gp140, formulated with GSK Biologicals’ AS01 adjuvant for intramuscular doses and an inert gel v
Description
CAVD 304 is a non-human primate study comparing intravaginal and intramuscular routes of administration of a protein and adjuvant regimen.
Sign in to see full information about this study and to download study data.
Products
HIV-1 gp140 Carbopol 974P GSK AS01Integrated data
NAb
Non-integrated data
No non-integrated data is available for this study.